Viracta Therapeutics IncNASDAQ:VIRXNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.1767
- TODAY'S CHANGE (%)-0.0045 (-2.4834%)
- Bid / Lots0.1770/ 11
- Ask / Lots0.1817/ 103
- Open / Previous Close0.1812 / 0.1812
- Day Range
- 52 Week Range
- Volume439,039
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | VIRX |
|---|---|---|
| 09:32 ET | 21001 | 0.181 |
| 09:37 ET | 1100 | 0.18 |
| 09:44 ET | 100 | 0.1806 |
| 09:46 ET | 11815 | 0.1827 |
| 09:48 ET | 8163 | 0.1794 |
| 09:55 ET | 2000 | 0.1806 |
| 09:57 ET | 12300 | 0.1788 |
| 10:02 ET | 5300 | 0.178 |
| 10:04 ET | 3031 | 0.1766 |
| 10:09 ET | 768 | 0.177 |
| 10:11 ET | 16242 | 0.1767 |
| 10:20 ET | 8199 | 0.1776 |
| 10:22 ET | 5604 | 0.1775 |
| 10:24 ET | 11311 | 0.182 |
| 10:26 ET | 109 | 0.1801 |
| 10:27 ET | 6000 | 0.1799 |
| 10:29 ET | 200 | 0.1793 |
| 10:36 ET | 450 | 0.1782 |
| 10:38 ET | 5150 | 0.1778 |
| 10:40 ET | 5000 | 0.1797 |
| 10:44 ET | 155 | 0.1816 |
| 10:49 ET | 1658 | 0.1828 |
| 10:58 ET | 6700 | 0.1797 |
| 11:00 ET | 1000 | 0.178001 |
| 11:05 ET | 1200 | 0.1819 |
| 11:07 ET | 8700 | 0.18 |
| 11:09 ET | 3480 | 0.1818 |
| 11:12 ET | 200 | 0.1801 |
| 11:18 ET | 11219 | 0.1784 |
| 11:20 ET | 38627 | 0.1775 |
| 11:21 ET | 800 | 0.1771 |
| 11:23 ET | 2963 | 0.1769 |
| 11:27 ET | 2330 | 0.18 |
| 11:30 ET | 600 | 0.17915 |
| 11:32 ET | 400 | 0.1793 |
| 11:34 ET | 4339 | 0.1818 |
| 11:36 ET | 699 | 0.1801 |
| 11:38 ET | 498 | 0.182 |
| 11:39 ET | 250 | 0.18 |
| 11:43 ET | 190 | 0.181 |
| 11:45 ET | 299 | 0.1805 |
| 11:52 ET | 26401 | 0.1788 |
| 11:54 ET | 1300 | 0.17765 |
| 12:08 ET | 500 | 0.1781 |
| 12:35 ET | 129 | 0.1815 |
| 12:51 ET | 100 | 0.1774 |
| 01:02 ET | 30000 | 0.1766 |
| 01:04 ET | 3600 | 0.1795 |
| 01:06 ET | 3700 | 0.1813 |
| 01:08 ET | 400 | 0.1802 |
| 01:09 ET | 1600 | 0.1802 |
| 01:27 ET | 2400 | 0.181 |
| 01:29 ET | 1900 | 0.1812 |
| 01:36 ET | 750 | 0.18 |
| 01:38 ET | 3500 | 0.1809 |
| 01:44 ET | 400 | 0.1799 |
| 01:45 ET | 500 | 0.181 |
| 01:49 ET | 30028 | 0.178 |
| 01:51 ET | 100 | 0.1781 |
| 01:56 ET | 4532 | 0.1766 |
| 02:00 ET | 1000 | 0.1766 |
| 02:03 ET | 2900 | 0.1813 |
| 02:12 ET | 800 | 0.18 |
| 02:14 ET | 905 | 0.179 |
| 02:20 ET | 700 | 0.1811 |
| 02:21 ET | 5000 | 0.181 |
| 02:30 ET | 360 | 0.1789 |
| 02:32 ET | 100 | 0.1796 |
| 02:34 ET | 900 | 0.1811 |
| 02:41 ET | 500 | 0.1789 |
| 02:45 ET | 350 | 0.181 |
| 02:50 ET | 2215 | 0.1811 |
| 03:03 ET | 5400 | 0.181 |
| 03:15 ET | 700 | 0.179 |
| 03:19 ET | 600 | 0.1799 |
| 03:26 ET | 10000 | 0.1799 |
| 03:28 ET | 1300 | 0.1799 |
| 03:30 ET | 30860 | 0.1795 |
| 03:37 ET | 1000 | 0.1791 |
| 03:42 ET | 1000 | 0.179 |
| 03:44 ET | 911 | 0.1791 |
| 03:46 ET | 1192 | 0.1803 |
| 03:48 ET | 1079 | 0.179 |
| 03:50 ET | 100 | 0.1791 |
| 03:51 ET | 800 | 0.1772 |
| 03:57 ET | 2100 | 0.1769 |
| 04:00 ET | 3201 | 0.1767 |
Nov 6, 2024
*DJ Viracta Therapeutics Announces Reprioritization of Resources, from 4:44PM ET on Wednesday Nov 06, 2024 by Dow Jones
4:44PM ET on Wednesday Nov 06, 2024 by Dow JonesViracta Therapeutics Announces Reprioritization of Resources to Enhance Focus on Nana-val Development Program in Patients with Relapsed or Refractory EBV-Positive Peripheral T-Cell Lymphoma, from 4:30PM ET on Wednesday Nov 06, 2024 by Dow Jones
4:30PM ET on Wednesday Nov 06, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Viracta Therapeutics Inc | 7.1M | -0.2x | --- |
Moleculin Biotech Inc | 7.1M | -0.2x | --- |
Mosaic Immunoengineering Inc | 7.2M | -6.0x | --- |
Cyclerion Therapeutics Inc | 7.0M | -0.5x | --- |
Transcode Therapeutics Inc | 6.9M | 0.0x | --- |
Edesa Biotech Inc | 7.6M | -1.1x | --- |
Company Information
Viracta Therapeutics, Inc. is a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers, which impact patients worldwide. The Company’s lead product candidate is an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively, Nana-val). Nana-val is being evaluated in multiple ongoing clinical trials, including a pivotal, global, multicenter, open-label Phase II basket trial for the treatment of multiple subtypes of relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) lymphoma (NAVAL-1), as well as a multinational, open-label Phase Ib/II clinical trial for the treatment of patients with recurrent or metastatic (R/M) EBV + nasopharyngeal carcinoma (NPC) and other advanced EBV + solid tumors. The Company is also pursuing the application of its Kick and Kill approach in other virus-related cancers.
Contact Information
- Headquarters
- 2533 S COAST HWY 101, SUITE 210CARDIFF BY THE SEA, CA, United States 92007
- Phone
- 858-400-8470
- Fax
- 650-266-3501
Executives
- Independent Chairman of the Board
- Roger Pomerantz
- President, Chief Executive Officer, Director
- Mark Rothera
- Chief Financial Officer
- Michael Faerm
- Senior Vice President - Finance
- Melody Burcar
- Chief Medical Officer
- Darrel Cohen
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $7.1M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 39.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.73 |
EPS | $-1.16 |
Book Value | $0.47 |
P/E Ratio | -0.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
